Rapamycin treatment for a child with germline PTEN mutation

    loading  Checking for direct PDF access through Ovid



A 9-month-old boy with Proteus syndrome and a de novo germline mutation in the tumor suppressor PTEN was referred to a specialist centre for management. Over the first years of life, the patient developed life-threatening respiratory dysfunction and malnutrition because of progressive growth of hamartomas affecting the chest, mediastinum, abdomen and pelvis.


Physical examination, CT scans of the mediastinum, pelvis and abdomen, measurement of serum insulin-like growth factor binding protein-2, and investigation of the effect of the PTEN mutation on phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling in an in vitro cell model.


PTEN hamartoma tumor syndrome, specifically Proteus syndrome.


Oral rapamycin.

Related Topics

    loading  Loading Related Articles